- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Fludarabine Phosphate, Cyclophosphamide, Rituximab
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 66 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2014
- U.S. locations
- 1
- States / cities
- Houston, Texas
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 1,003
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Oral Mucositis
- Interventions
- Virgin Coconut Oil
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 7 Years to 26 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2036
- U.S. locations
- 1
- States / cities
- Charlotte, North Carolina
- Conditions
- Hodgkin Lymphoma
- Interventions
- Brentuximab Vedotin, Doxorubicin, Vincristine, Rituximab
- Drug
- Lead sponsor
- Mitchell Cairo
- Other
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Valhalla, New York
- Conditions
- Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC)
- Interventions
- Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), FOLFOX, CAPOX, FOLFIRINOX
- Drug
- Lead sponsor
- Phanes Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 258 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 11
- States / cities
- Duarte, California • Los Angeles, California • Denver, Colorado + 8 more
- Conditions
- Breast Cancer
- Interventions
- OCPM Immunotherapeutic Vaccine
- Biological
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Ovarian Cancer
- Interventions
- carboplatin, cyclophosphamide, mitoxantrone hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support
- Drug · Procedure
- Lead sponsor
- Loyola University
- Other
- Eligibility
- Up to 64 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1991 – 2005
- U.S. locations
- 1
- States / cities
- Maywood, Illinois
- Conditions
- Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma
- Interventions
- Fine-Needle Aspiration, Irinotecan, Irinotecan Hydrochloride, Lurbinectedin
- Procedure · Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Endometrial Neoplasms
- Interventions
- Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
- Biological · Drug · Radiation
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 29
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
- Conditions
- Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
- Interventions
- Autologous Hematopoietic Stem Cell Transplantation, Best Available Therapy (BAT)
- Procedure · Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 156 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2029
- U.S. locations
- 22
- States / cities
- Palo Alto, California • Aurora, Colorado • Evanston, Illinois + 17 more
- Conditions
- Mantle Cell Lymphoma
- Interventions
- Bortezomib, Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin, Methotrexate, Rituximab, Vincristine
- Drug · Biological
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lymphoma
- Interventions
- busulfan, cyclophosphamide, etoposide, allogeneic bone marrow transplantation, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation, radiation therapy
- Drug · Procedure · Radiation
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 15 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2004
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Untreated Childhood Acute Lymphoblastic Leukemia
- Interventions
- doxorubicin hydrochloride, cyclophosphamide, methotrexate, rasburicase, leucovorin calcium, prednisone, methylprednisolone, filgrastim, rituximab, cytarabine, etoposide, vincristine sulfate, hydrocortisone sodium succinate, laboratory biomarker analysis
- Drug · Biological · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 1 Year to 29 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2014
- U.S. locations
- 1
- States / cities
- Arcadia, California
- Conditions
- Multiple Myeloma and Plasma Cell Neoplasm
- Interventions
- carmustine, cisplatin, cyclophosphamide, dexamethasone, etoposide, gemcitabine hydrochloride, melphalan, paclitaxel, bone marrow ablation with stem cell support, peripheral blood stem cell transplantation
- Drug · Procedure
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years to 70 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2002
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Adult Non-Hodgkin Lymphoma, Adult Grade III Lymphomatoid Granulomatosis, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
- Interventions
- lenalidomide, rituximab, polymerase chain reaction, nucleic acid sequencing, polymorphism analysis, flow cytometry, laboratory biomarker analysis
- Drug · Biological · Genetic + 1 more
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Cleveland, Ohio • Mayfield Heights, Ohio
- Conditions
- Metastatic Medulloblastoma, High Risk Supratentorial PNET, Metastatic PNET
- Interventions
- Carboplatin, Vincristine, 24 Gy
- Drug · Radiation
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 3 Years to 25 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2020
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Cancer
- Interventions
- filgrastim, carboplatin, cisplatin, cyclophosphamide, etoposide, ifosfamide, mesna, paclitaxel, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 33 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1994 – 2015
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Adult Supratentorial Primitive Neuroectodermal Tumor (PNET), Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
- Interventions
- etoposide, ifosfamide, intensity-modulated radiation therapy, topotecan hydrochloride, busulfan, melphalan, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, autologous bone marrow transplantation
- Drug · Radiation · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 6 Months to 40 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
- Interventions
- VS-6766/avutometinib, Cetuximab, Pill Diary
- Drug · Other
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cervical Cancer
- Interventions
- Treatment with Electronic Brachytherapy
- Device
- Lead sponsor
- Xoft, Inc.
- Industry
- Eligibility
- Female only
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Acute Myelogenous Leukemia
- Interventions
- cenersen, Idarubicin, Cytarabine
- Drug
- Lead sponsor
- Eleos, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 6
- States / cities
- La Jolla, California • Miami, Florida • St Louis, Missouri + 3 more
- Conditions
- Neuroblastoma, Lymphoma, High-risk Tumor
- Interventions
- CD133+ selected autologous stem cell infusion, IL-2, hu14.18K322A, Busulfan, Melphalan, GM-CSF, Bendamustine, Etoposide, Cytarabine, Carboplatin, Haploidentical natural killer cell infusion, G-CSF, Etoposide phosphate, CliniMACS
- Biological · Drug · Device
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 21 Years
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Memphis, Tennessee
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Idasanutlin, Cytarabine, Daunorubicin, Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
- Drug · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 9 more
- Conditions
- HIV Infections
- Interventions
- VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy
- Drug
- Lead sponsor
- ViiV Healthcare
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Bakersfield, California • DeLand, Florida • Newark, New Jersey
- Conditions
- Metastatic Melanoma
- Interventions
- High Dose Interleukin-2 (IL-2), ACT with TIL Infusion, Vemurafenib, Lymphodepletion
- Drug · Procedure
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2025
- U.S. locations
- 1
- States / cities
- Tampa, Florida